Senior Associate, Commercial Analytics at Roivant Sciences

New York, New York, United States

Apply Now

Not SpecifiedCompensation

Senior (5 to 8 years)Experience Level

Full TimeJob Type

UnknownVisa

BiopharmaceuticalIndustries

Requirements

At least five-years biopharma experience combining analytical, operational, and strategic skill sets
At least two-years of direct biopharma payer/pricing or related commercial experience required
Strong financial modeling capabilities and understanding of financial fundamentals
Bachelor’s degree required
Excellent written and verbal communication skills
Ability to synthesize material for board level or C-suite communications
Proficient in Excel and PowerPoint use
Ability to work independently and collaboratively in a fast-paced, matrixed team environment consisting of internal and external team members
Ability to generate action through influence and engagement
Analytical thinker with excellent problem-solving skills and the ability to adapt to changing priorities and deadlines
Excellent planning, organization and time management skills including the ability to support and prioritize multiple projects

Responsibilities

Model and maintain commercial revenue forecasts
Conduct ad-hoc market, pricing and payer analyses
Track industry trends and competitor performance
Support commercial diligence for new product opportunities
Liaison with the Real-World Evidence Team to design claims analyses to support commercial decision making
Improve current processes and coordinate organizational procedures for optimized efficiency and productivity
Manage commercial team rotational analysts

Skills

commercial forecasting

revenue modeling

market analysis

pricing analysis

payer analysis

competitor analysis

commercial diligence

real-world evidence

claims analysis

Roivant Sciences

Develops biopharmaceuticals and RNA therapeutics

About Roivant Sciences

Roivant Sciences develops and delivers medicines and technologies aimed at improving patient health, focusing on drug candidates for genetic disorders and RNA therapeutics. The company operates in the biopharmaceutical market, which involves creating drugs from biological sources. Roivant's unique business model combines in-house development with strategic partnerships, allowing it to build a strong pipeline of drug candidates and utilize advanced technologies to meet medical needs. A key subsidiary, Genevant, specializes in RNA therapeutics, employing proprietary delivery platforms for mRNA, RNAi, and gene editing to treat specific diseases. Roivant generates revenue through drug development, licensing agreements, and partnerships, with the goal of bringing innovative treatments to market efficiently.

New York City, New YorkHeadquarters

2014Year Founded

$1,750.9MTotal Funding

IPOCompany Stage

Biotechnology, HealthcareIndustries

201-500Employees

Benefits

Remote Work Options

Risks

Integration challenges from Dermavant acquisition may disrupt operations and delay development.

Regulatory hurdles in Pulmovant collaboration with Bayer could impede progress.

Failure of lupus drug brepocitinib may lead to financial losses and investor concerns.

Differentiation

Roivant Sciences focuses on late-stage drug candidates, reducing development time and cost.

The company builds Vants, nimble biotech firms, to enhance drug development efficiency.

Roivant leverages RNA therapeutics, including mRNA and RNAi, for innovative treatments.

Upsides

Roivant's acquisition of Dermavant expands its dermatology portfolio and therapeutic areas.

Strategic partnerships with Bayer and Roche accelerate drug development and market entry.

Increased investment from financial institutions highlights confidence in Roivant's growth potential.

Land your dream remote job 3x faster with AI

Try Jobo Free